Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Healing & Recovery•Updated 2026-02-01•7 min read

    What Is BPC-157? Benefits, Research & Safety

    A pentadecapeptide derived from human gastric juice, extensively researched for its potential tissue repair and regenerative properties across multiple organ systems.

    Share:X PostLinkedIn
    Also known as:
    Body Protection Compound-157
    Pentadecapeptide BPC 157
    PL 14736
    DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Prohibited in sport

    UK summary: Not a licensed UK medicine. Promising preclinical data (mostly animal studies) but robust human evidence is lacking. Marketed online as 'research only'. Treated by WADA as prohibited under the S0 non-approved substances category.

    Quick Facts

    Category
    Healing & Recovery
    Half-Life
    Estimated 4-6 hours based on limited pharmacokinetic data from preclinical studies
    UK Status
    Not a licensed medicine. Available only as a research chemical. Not approved by MHRA for human therapeutic use.
    EU Status
    Not authorised for human use by the European Medicines Agency. Classified as a research compound in most member states.

    Overview

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids derived from a protective protein naturally found in human gastric juice. This peptide has garnered significant research interest due to its remarkable stability and apparent regenerative properties observed in numerous preclinical studies. The peptide's molecular formula is C62H98N16O22, with a molecular weight of approximately 1419.5 g/mol. Unlike many peptides that degrade rapidly in the digestive system, BPC-157 demonstrates unusual stability in gastric acid, which has led researchers to investigate both injectable and oral administration routes. Research interest in BPC-157 has expanded considerably since its initial characterisation, with studies exploring its effects on tendons, ligaments, muscles, the gastrointestinal tract, bones, and even the nervous system. The peptide appears to work through multiple interconnected mechanisms, making it a subject of ongoing scientific investigation. BPC-157 is classified as a research peptide and is not approved for human therapeutic use by any major regulatory authority including the MHRA or EMA. All information presented here is for educational purposes based on published research.
    Evidence standards summary

    BPC-157 — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

    Not a licensed UK medicine. Promising preclinical data (mostly animal studies) but robust human evidence is lacking. Marketed online as 'research only'. Treated by WADA as prohibited under the S0 non-approved substances category.

    02Human evidence grade

    ETheoretical / insufficientStrength of evidence from published human trials.

    03Preclinical evidence grade

    CLimited human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Not a licensed medicine. Available only as a research chemical. Not approved by MHRA for human therapeutic use.
    • EU: Not authorised for human use by the European Medicines Agency. Classified as a research compound in most member states.
    • Notes: BPC-157 remains an investigational compound without approval from any major regulatory authority including the FDA, MHRA, or EMA. Its use is entirely at individual risk and should only be considered under appropriate medical supervision. The peptide is prohibited in competitive sports by WADA.

    05Approved medical uses

    None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

    06Unapproved / promotional claims

    • Heals tendon and ligament injuries
    • Regenerates gut lining and reverses IBD
    • Accelerates post-surgical recovery
    • Anti-inflammatory ‘body protection’ for athletes

    07Common internet claims

    • Cures leaky gut
    • Faster than physio for soft-tissue injury
    • Safe with no side effects (animal data extrapolated)
    • Combine with TB-500 for the ‘ultimate healing stack’

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Heals tendon and ligament injuries”DNoHighPreclinical (animal) studies suggest effects on tendon tissue; robust human RCTs are lacking.
    “Repairs the gut and treats IBD”DNoHighAnimal models show gastrointestinal effects; human GI-disease evidence is not established.
    “Safe and side-effect free”ENoHighLong-term human safety has not been established. Adverse-event monitoring outside trials is informal.
    “Pharma-grade and clinically proven”ENoHighBPC-157 has no UK marketing authorisation; grey-market product is not independently verified for identity or purity.
    “Used by elite athletes for faster recovery”ENoHighBPC-157 is treated by WADA as prohibited under S0. Athletes face strict-liability anti-doping risk.

    09Safety uncertainty score

    High

    Limited human safety data; meaningful uncertainty about rare or long-term effects.

    10Known adverse signals

    • Long-term human safety not established
    • Theoretical angiogenic effects not characterised in humans
    • Sterility and identity risk from grey-market supply
    • WADA S0 strict-liability risk for athletes

    11Drug-interaction uncertainty

    High

    Interaction picture sparse; meaningful uncertainty when combined with other medicines.

    12Anti-doping status

    WADA: Prohibited in sportWADA strict-liability framing applies.

    13UK legal position

    UK: Sold as 'research only' (UK)

    Not a licensed medicine. Available only as a research chemical. Not approved by MHRA for human therapeutic use.

    Read the full UK legal guide → BPC-157 legal status in the UK

    14EU legal position

    Not authorised for human use by the European Medicines Agency. Classified as a research compound in most member states.

    15What this page cannot tell you

    • Whether BPC-157 is safe or appropriate for you as an individual.
    • What dose, frequency, or duration is right for any human condition.
    • Whether the product you might encounter is what its label claims.
    • How long-term BPC-157 exposure affects human tumour-relevant tissues.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • No completed UK or EU human RCTs for any indication.
    • Pharmacokinetics in humans largely uncharacterised.
    • Long-term safety unknown.
    • No standardised manufacturing or batch-purity assurance in research-peptide supply.

    19Safer alternatives / established care pathways

    • Evidence-based physiotherapy for tendon and ligament injuries.
    • Licensed anti-inflammatory medicines under clinical supervision.
    • Surgical and endoscopic management for diagnosed IBD per NICE guidance.

    Related Safety Centre page → Unlicensed peptide risks

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is BPC-157 a licensed UK medicine for any condition?
    • What does the human evidence look like beyond animal studies?
    • If I'm an athlete, what does WADA's S0 category mean for me?
    • What contamination or counterfeit risk should I be aware of?
    • Are there licensed alternatives for the underlying issue I'm trying to address?
    • How would suspected side effects be reported (Yellow Card)?

    Discovery & History

    BPC-157 was first isolated and characterised by Professor Predrag Sikirić and his research team at the University of Zagreb, Croatia, in the early 1990s. The peptide was derived from a larger protective protein identified in human gastric juice, which demonstrated remarkable cytoprotective properties. Initial research focused on the gastro-protective capabilities of the compound, with early studies demonstrating its ability to protect against various forms of gastrointestinal damage including ulcers, inflammatory bowel conditions, and mucosal lesions. The name "Body Protection Compound" reflects these early findings regarding its protective effects. Throughout the 1990s and 2000s, the research team in Zagreb expanded their investigations to explore BPC-157's effects beyond the gastrointestinal system. Studies began to emerge showing potential benefits for musculoskeletal injuries, leading to increased interest from the sports medicine and regenerative medicine research communities. The peptide sequence was patented, and over 100 research papers have been published examining various aspects of BPC-157's biological activity. While the majority of research has been conducted in animal models, the consistent positive findings across numerous studies have generated considerable interest in potential clinical applications. Research continues to this day, with ongoing investigations into the peptide's mechanisms of action and potential therapeutic applications across a range of conditions.

    Mechanism of Action

    BPC-157 is believed to exert its biological effects through multiple interconnected molecular pathways, though the precise mechanisms remain subjects of ongoing research. Current understanding suggests the following key mechanisms: **Growth Factor Modulation** Research indicates that BPC-157 may significantly upregulate the expression of various growth factors critical for tissue repair. Vascular Endothelial Growth Factor (VEGF) appears to be particularly affected, potentially explaining the peptide's observed angiogenic properties. Studies also suggest effects on Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), and other growth factors involved in tissue regeneration. **Nitric Oxide System Interaction** BPC-157 appears to interact extensively with the nitric oxide (NO) system, which plays crucial roles in vasodilation, blood flow regulation, and tissue healing. Research suggests the peptide may modulate NO synthase activity, potentially enhancing blood supply to injured tissues and promoting the delivery of nutrients and oxygen essential for repair. **FAK-Paxillin Pathway Activation** Studies indicate that BPC-157 may influence the FAK (Focal Adhesion Kinase) and paxillin signalling pathway. This pathway is fundamental to cell adhesion, migration, and tissue remodelling processes. By modulating this pathway, BPC-157 may facilitate the organised movement of cells to injury sites and their proper integration into healing tissue. **Anti-Inflammatory Effects** Some research suggests BPC-157 possesses anti-inflammatory properties, potentially through modulation of cytokine production and inflammatory signalling cascades. Reduced inflammation at injury sites may contribute to accelerated healing and reduced scar tissue formation. **Dopaminergic and Serotonergic System Effects** Interestingly, research has demonstrated that BPC-157 may interact with both dopaminergic and serotonergic neurotransmitter systems. Studies have shown effects on dopamine and serotonin receptor expression, which may explain some of the neuroprotective properties observed in research models. **Tendon and Ligament Repair** In tendon injury models, BPC-157 has been observed to stimulate tendon fibroblast activity and enhance collagen synthesis. The peptide appears to promote the organised deposition of collagen fibres, potentially resulting in stronger and more functional tissue repair.

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Accelerated tendon and ligament healing demonstrated in multiple animal models with improved tensile strength
    • 2
      Enhanced muscle tissue repair following injury with reduced recovery time in preclinical studies
    • 3
      Gastric mucosal protection and accelerated healing of gastrointestinal lesions
    • 4
      Improved wound healing rates and tissue regeneration in various injury models
    • 5
      Potential bone healing enhancement through effects on osteoblast activity
    • 6
      Neuroprotective effects observed in models of brain injury and neurotoxicity
    • 7
      Possible cardioprotective properties in certain experimental models
    • 8
      Anti-inflammatory effects potentially reducing tissue damage in inflammatory conditions

    Claim vs Evidence

    How popular claims about BPC-157 stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Heals tendon and ligament injuries”DNoHighPreclinical (animal) studies suggest effects on tendon tissue; robust human RCTs are lacking.
    “Repairs the gut and treats IBD”DNoHighAnimal models show gastrointestinal effects; human GI-disease evidence is not established.
    “Safe and side-effect free”ENoHighLong-term human safety has not been established. Adverse-event monitoring outside trials is informal.
    “Pharma-grade and clinically proven”ENoHighBPC-157 has no UK marketing authorisation; grey-market product is not independently verified for identity or purity.
    “Used by elite athletes for faster recovery”ENoHighBPC-157 is treated by WADA as prohibited under S0. Athletes face strict-liability anti-doping risk.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical Dosage200-500 mcg per administration (extrapolated from preclinical research data)
    Frequency1-2 times daily, typically for localised injury support
    Duration4-12 weeks depending on the nature of the research application
    NotesThese are theoretical protocols derived from research literature extrapolation. No standardised human dosing protocols exist as BPC-157 is not approved for human use. Subcutaneous administration near the site of interest has been common in research settings. Always consult a qualified healthcare professional before considering any peptide.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (most commonly studied in research)
    • Intramuscular injection (studied in some protocols)
    • Oral administration (research suggests stability in gastric acid)
    • Topical application (limited research in wound healing)
    Half-LifeStability
    Estimated 4-6 hours based on limited pharmacokinetic data from preclinical studiesNotably stable in gastric acid environments unlike many peptides; lyophilised powder should be stored at -20°C for long-term storage; reconstituted solution stable at 2-8°C for limited periods

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Injection site reactions including temporary redness, swelling, or discomfort
    • Mild nausea reported anecdotally in some cases
    • Temporary dizziness or lightheadedness (rare reports)
    • Fatigue or changes in energy levels (infrequent)

    Rare Risks & Concerns

    • Allergic or hypersensitivity reactions (theoretical risk with any peptide)
    • Unknown long-term effects in humans due to lack of clinical trials
    • Potential interactions with other medications or compounds (not well characterised)
    • Theoretical concerns regarding effects on tumour angiogenesis due to VEGF modulation

    Contraindications

    • Pregnancy and breastfeeding (no safety data available)
    • Active cancer or history of cancer (theoretical concern due to angiogenic properties)
    • Known allergies to peptides or any component of the formulation
    • Children and adolescents (no paediatric safety data)
    • Individuals with autoimmune conditions (effects not well studied)

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Not a licensed medicine. Available only as a research chemical. Not approved by MHRA for human therapeutic use.

    🇪🇺 European Union

    Not authorised for human use by the European Medicines Agency. Classified as a research compound in most member states.

    BPC-157 remains an investigational compound without approval from any major regulatory authority including the FDA, MHRA, or EMA. Its use is entirely at individual risk and should only be considered under appropriate medical supervision. The peptide is prohibited in competitive sports by WADA.

    Clinical Studies Summary

    BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Angiogenesis, and Tissue Regeneration

    Comprehensive review examining BPC-157's interactions with angiogenic growth factors and its effects on tissue healing across multiple organ systems. The review highlighted consistent cytoprotective and regenerative effects observed across numerous preclinical studies.

    Curr Pharm Des. 2018View on PubMed

    Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract

    Review of BPC-157's potential applications in gastrointestinal conditions including inflammatory bowel disease, ulcers, and fistulas. Highlighted the peptide's unique stability and multi-target activity.

    Curr Pharm Des. 2011View on PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown.

    Am J Sports Med. 2026View on PubMed

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

    Inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials. BPC-157 remains a promising candidate for regenerative medicine, yet comprehensive evaluation is required before clinical translation can be recommended.

    Int J Mol Sci. 2026View on PubMed

    New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.

    Here, as concept resolution, we review the counteraction of advanced Virchow triad circumstances by activation of the collateral rescuing pathways, depending on injury, activated azygos vein direct blood flow delivery, to counteract occlusion/occlusion-like syndromes starting with the context of alcohol-stomach lesions.

    Inflammopharmacology. 2024View on PubMed

    Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future.

    BPC 157 also has an effect on blood vessels, resulting in vessel recruitment that circumvents vessel occlusion and the development of additional shunting and rapid bypass loops to rapidly reestablish the integrity of blood flow (ischemic/reperfusion colitis, duodenal lesions, cecal perforation, and inferior vena caval occlusion).

    Gut Liver. 2020View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    1
    Currently recruiting
    1
    Furthest phase
    Phase 2
    Approved product
    No

    BPC 157 for Acute Hamstring Muscle Strain Repair

    PHASE2

    Status: Recruiting · 120 participants · Hudson Biotech

    Conditions: Hamstring Muscle Strain, Skeletal Muscle Injury

    No results postedNCT07437547

    Adverse event reports (FDA FAERS)

    Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for BPC-157?

    Source research-grade BPC-157 from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about BPC-157

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Is BPC-157 a licensed UK medicine for any condition?
    • What does the human evidence look like beyond animal studies?
    • If I'm an athlete, what does WADA's S0 category mean for me?
    • What contamination or counterfeit risk should I be aware of?
    • Are there licensed alternatives for the underlying issue I'm trying to address?
    • How would suspected side effects be reported (Yellow Card)?

    UK regulatory & safety context

    BPC-157 legal status in the UK

    UK legal reference

    Unlicensed peptide risks

    Safety Centre guide

    Related Research Guides

    Peptides for Skin Health

    Read guide

    Peptides for Skin Firmness

    Read guide

    Peptides for Tendon Injuries

    Read guide

    Peptides for Immune Support

    Read guide

    Peptides for Joint Health

    Read guide

    Peptides for Gut Health

    Read guide

    Peptide Comparisons

    BPC-157 vs TB-500

    Compare peptides

    BPC-157 vs GHK-Cu

    Compare peptides

    Combination Protocols

    BPC-157 + TB-500 Healing Stack

    View protocol

    BPC-157 + GHK-Cu Skin Healing Stack

    View protocol

    BPC-157 + GHK-Cu Gut Healing Stack

    View protocol

    GHK-Cu + Matrixyl + BPC-157 Triple-Pathway Collagen Stack

    View protocol

    Related Peptides

    TB-500

    A synthetic version of the naturally occurring peptide Thymosin Beta-4, extensively researched for its roles in tissue repair, cell migration, and angiogenesis.

    Learn more

    GHK-Cu

    A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.

    Learn more

    Thymosin Beta-4

    A 43-amino acid peptide naturally present in all cells, fundamental to tissue repair, cell migration, and regeneration processes throughout the body.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.